In-vitro and in-vivo efficacy of ceftriaxone, moxalactam, and chloramphenicol against Haemophilus influenzae type b.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology; D002443:Ceftriaxone; D002511:Cephalosporins / Q000494:pharmacology*; D002513:Cephamycins / Q000097:blood / Q000494:pharmacology*; D002701:Chloramphenicol / Q000494:pharmacology*; D006192:Haemophilus Infections / Q000188:drug therapy; D006193:Haemophilus influenzae / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D009070:Moxalactam; D051381:Rats
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002513:Cephamycins; D002701:Chloramphenicol; D002443:Ceftriaxone; D002439:Cefotaxime; D009070:Moxalactam